Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748969 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Growth Hormone in MPS I, II, and VI
A Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00748969: Clinical Trial Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
NCT00748969 is a Phase 2 study that was terminated before completion, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00748969, a Phase 2 study, was terminated before completion, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
Interventions
- DRUG Somatropin (DNA origin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Why NCT00748969 stopped before completion
NCT00748969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Somatropin (DNA origin) is the first listed.
NCT00748969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00748969 about?
NCT00748969 is a clinical study titled "Clinical Trial of Growth Hormone in MPS I, II, and VI". The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
What is the current status of trial NCT00748969?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00748969?
The interventions under investigation include: Somatropin (DNA origin) (DRUG).
Who is sponsoring clinical trial NCT00748969?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00748969's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia